The biotech's shares ripped higher last month in response to Gilead Sciences (NASDAQ: GILD) exercising its options to develop four of the company's clinical-stage cancer compounds. Specifically, Gilead decided to go forth with the development of two anti-TIGIT antibodies, an A2a/2bR antagonist, as well as a small molecule CD73 inhibitor. Arcus, in turn, received a hefty $725 million upfront payment for the right to develop these four anti-cancer compounds.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting